Xiaolin Xiao

1.4k total citations
34 papers, 844 citations indexed

About

Xiaolin Xiao is a scholar working on Molecular Biology, Hematology and Epidemiology. According to data from OpenAlex, Xiaolin Xiao has authored 34 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 7 papers in Hematology and 6 papers in Epidemiology. Recurrent topics in Xiaolin Xiao's work include Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (5 papers) and Ubiquitin and proteasome pathways (4 papers). Xiaolin Xiao is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (5 papers) and Ubiquitin and proteasome pathways (4 papers). Xiaolin Xiao collaborates with scholars based in China, United Kingdom and Greece. Xiaolin Xiao's co-authors include Xiao Ma, Qichao Hu, Xinyu Deng, Jinhao Zeng, Anastasios Karadimitris, Valentina S. Caputo, Yinxiao Jiang, Wenwen Zhang, Jing Jiang and Kikkeri N. Naresh and has published in prestigious journals such as Nature Communications, Blood and Cancer Cell.

In The Last Decade

Xiaolin Xiao

33 papers receiving 837 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaolin Xiao China 17 377 230 152 106 87 34 844
Tae‐Hwe Heo South Korea 18 429 1.1× 191 0.8× 248 1.6× 99 0.9× 58 0.7× 64 1.0k
Pan Shen China 19 659 1.7× 160 0.7× 260 1.7× 112 1.1× 146 1.7× 59 1.4k
Xin Ba China 16 276 0.7× 122 0.5× 176 1.2× 80 0.8× 113 1.3× 30 816
Mei Zhang China 17 334 0.9× 133 0.6× 140 0.9× 74 0.7× 120 1.4× 54 842
Tingting Long China 18 350 0.9× 136 0.6× 157 1.0× 129 1.2× 65 0.7× 56 988
Xiong Li China 13 254 0.7× 150 0.7× 156 1.0× 66 0.6× 102 1.2× 38 849
Zhiwei Zhang China 18 416 1.1× 285 1.2× 110 0.7× 34 0.3× 61 0.7× 46 917
Xiaoyun Shen China 21 632 1.7× 183 0.8× 137 0.9× 110 1.0× 27 0.3× 51 1.3k

Countries citing papers authored by Xiaolin Xiao

Since Specialization
Citations

This map shows the geographic impact of Xiaolin Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaolin Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaolin Xiao more than expected).

Fields of papers citing papers by Xiaolin Xiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaolin Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaolin Xiao. The network helps show where Xiaolin Xiao may publish in the future.

Co-authorship network of co-authors of Xiaolin Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaolin Xiao. A scholar is included among the top collaborators of Xiaolin Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaolin Xiao. Xiaolin Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Yantao, Yu Peng, Zongran Liu, et al.. (2025). Tumor-associated macrophage-derived exosomes modulate the immunotherapeutic sensitivity of SHH-medulloblastoma by targeting m6A-modified FOXD1. Neuro-Oncology. 27(11). 3000–3015. 1 indexed citations
2.
He, Xuan, Yubing Li, Xinyu Deng, Xiaolin Xiao, & Jinhao Zeng. (2023). Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses. Frontiers in Pharmacology. 14. 1230783–1230783. 17 indexed citations
3.
Shen, Yao, Ioannis V. Kostopoulos, Xiaolin Xiao, et al.. (2022). Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood. 139(13). 1939–1953. 20 indexed citations
4.
Lai, Zetian, Xiaolin Xiao, Lihua Xie, et al.. (2022). Development and evaluation of an efficient and real-time monitoring system for the vector mosquitoes, Aedes albopictus and Culex quinquefasciatus. PLoS neglected tropical diseases. 16(9). e0010701–e0010701. 2 indexed citations
5.
Chen, Xixi, et al.. (2022). Evidence construction of Huangkui capsule against chronic glomerulonephritis: A systematic review and network pharmacology. Phytomedicine. 102. 154189–154189. 11 indexed citations
6.
Zhou, Chao, et al.. (2022). Effects of long-term exposure to sevoflurane on the proliferation, migration, invasion, and cisplatin sensitivity of esophageal cancer. Translational Cancer Research. 11(5). 1045–1052. 1 indexed citations
7.
Chen, Nianzhi, Xiao Ma, Xiaolin Xiao, et al.. (2022). Rediscovery of Traditional Plant Medicine: An Underestimated Anticancer Drug of Chelerythrine. Frontiers in Pharmacology. 13. 906301–906301. 34 indexed citations
8.
Zhao, Maoyuan, Yi Yang, Qing Nian, et al.. (2022). Phytochemicals and mitochondria: Therapeutic allies against gastric cancer. Phytomedicine. 110. 154608–154608. 13 indexed citations
9.
Zhang, Fangling, Xiaolin Xiao, Yong Li, et al.. (2022). Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases. Frontiers in Pharmacology. 12. 805269–805269. 12 indexed citations
10.
Robinson, Mark E., Valentina S. Caputo, Xiaolin Xiao, et al.. (2021). The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma. Haematologica. 107(3). 721–732. 28 indexed citations
11.
Chaidos, Aristeidis, Philippa C. May, Xiaolin Xiao, et al.. (2021). Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma. Nature Communications. 12(1). 5450–5450. 26 indexed citations
12.
Zhang, Fangling, Xiaolin Xiao, Zhao Wu, et al.. (2021). Tripterygium hypoglaucum (Lévl.) Hutch and Its Main Bioactive Components: Recent Advances in Pharmacological Activity, Pharmacokinetics and Potential Toxicity. Frontiers in Pharmacology. 12. 715359–715359. 36 indexed citations
13.
Liu, Zhihao, Xiyun Bian, Jing Su, et al.. (2021). Rg3 promotes the SUMOylation of SERCA2a and corrects cardiac dysfunction in heart failure. Pharmacological Research. 172. 105843–105843. 33 indexed citations
14.
Wu, Zhao, Xinyu Deng, Qichao Hu, et al.. (2021). Houttuynia cordata Thunb: An Ethnopharmacological Review. Frontiers in Pharmacology. 12. 714694–714694. 87 indexed citations
15.
Xiao, Xiaolin, Qichao Hu, Xinyu Deng, et al.. (2021). Old wine in new bottles: Kaempferol is a promising agent for treating the trilogy of liver diseases. Pharmacological Research. 175. 106005–106005. 51 indexed citations
16.
Zhang, Wenwen, Fangling Zhang, Qichao Hu, et al.. (2021). The emerging possibility of the use of geniposide in the treatment of cerebral diseases: a review. Chinese Medicine. 16(1). 86–86. 31 indexed citations
17.
Caputo, Valentina S., Xiaolin Xiao, Mark E. Robinson, et al.. (2020). Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro. iScience. 24(1). 101989–101989. 13 indexed citations
18.
Rotolo, Antonia, Valentina S. Caputo, Monika Holubová, et al.. (2018). Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting. Cancer Cell. 34(4). 596–610.e11. 132 indexed citations
19.
Zhang, Bing, Xiaolin Xiao, Junqin Zong, et al.. (2017). Comparative transcriptome analysis provides new insights into erect and prostrate growth in bermudagrass (Cynodon dactylon L.). Plant Physiology and Biochemistry. 121. 31–37. 18 indexed citations
20.
Li, Shanliang, Jie Yan, Yanqiu Zhang, et al.. (2016). Niclosamide ethanolamine inhibits artery constriction. Pharmacological Research. 115. 78–86. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tae‐Hwe Heo Breakdown of academic impact, for papers by Pan Shen Breakdown of academic impact, for papers by Xin Ba Breakdown of academic impact, for papers by Mei Zhang Breakdown of academic impact, for papers by Tingting Long Breakdown of academic impact, for papers by Xiong Li Breakdown of academic impact, for papers by Zhiwei Zhang Breakdown of academic impact, for papers by Xiaoyun Shen
Rankless by CCL
2026